本文選題：SIRT-1　切入點(diǎn)：SUMO-1　出處：《青島大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:檢測(cè)SIRT-1(Silent information regulator 1)與SUMO-1(Small ubiquitin-related modifier-1)在不同子宮內(nèi)膜組織中的表達(dá)情況并推測(cè)其與內(nèi)膜癌發(fā)生發(fā)展之間可能的內(nèi)在聯(lián)系。方法:收集并保存2014年10月1日至2016年06月30日在青島大學(xué)附屬醫(yī)院婦科與青島市婦女兒童醫(yī)院婦科行手術(shù)切除后并經(jīng)病理確診的73例異常子宮內(nèi)膜組織,其中子宮內(nèi)膜癌組織45例(均為腺癌)、子宮內(nèi)膜不典型增生組織28例,同時(shí)選擇因單純子宮肌瘤行全子宮切除術(shù)后并經(jīng)病理確診為正常子宮內(nèi)膜標(biāo)本30例。應(yīng)用免疫組織化學(xué)方法及western-blot方法分別檢測(cè)SIRT-1蛋白與SUMO-1蛋白在各組子宮內(nèi)膜組織中的表達(dá)水平,利用統(tǒng)計(jì)學(xué)方法統(tǒng)計(jì)并分析其表達(dá)程度與子宮內(nèi)膜病變程度的關(guān)系以及其與子宮內(nèi)膜癌組織各項(xiàng)臨床病理參數(shù)之間的相關(guān)關(guān)系。結(jié)果:45例子宮內(nèi)膜癌患者年齡區(qū)間為35~73歲(52.85±8.41),其中50歲32例,占71.1%,≤50歲13例,占28.8%;(1)SIRT-1蛋白的陽性表達(dá)率在正常子宮內(nèi)膜組織、子宮內(nèi)膜不典型增生組織、子宮內(nèi)膜癌組織分別為6.67%、42.9%,62.2%且呈遞增趨勢(shì),差異有統(tǒng)計(jì)學(xué)意義(P0.05);(2)SUMO-1蛋白的陽性表達(dá)率在正常子宮內(nèi)膜組織、子宮內(nèi)膜不典型增生組織、子宮內(nèi)膜癌組織分別為6.67%、32.1%、55.6%且呈遞增趨勢(shì),差異有統(tǒng)計(jì)學(xué)意義(P0.05);(3)兩者共同陽性表達(dá)率在正常子宮內(nèi)膜組織、子宮內(nèi)膜不典型增生組織、子宮內(nèi)膜癌組織組中分別為0%、25.0%、42.2%且呈遞增趨勢(shì),差異有統(tǒng)計(jì)學(xué)意義(P0.05);(4)兩者各自在有淋巴結(jié)轉(zhuǎn)移組的陽性表達(dá)率明顯高于與淋巴結(jié)轉(zhuǎn)移陰性組(P0.05);且兩者各自與子宮內(nèi)膜癌組織學(xué)分化程度、淋巴結(jié)轉(zhuǎn)移及FIGO臨床分期有關(guān)(P0.05);而與內(nèi)膜癌分型、年齡無關(guān)(P0.05)。結(jié)論:SIRT-1與SUMO-1在子宮內(nèi)膜組織中的陽性表達(dá)率各自隨著正常子宮內(nèi)膜組織、子宮內(nèi)膜不典型增生組織、子宮內(nèi)膜癌的發(fā)展過程表現(xiàn)出增高趨勢(shì),且與內(nèi)膜癌的淋巴結(jié)轉(zhuǎn)移程度、子宮內(nèi)膜癌組織學(xué)分化程度、以及臨床分期相關(guān),同時(shí)兩者在子宮內(nèi)膜癌的發(fā)生發(fā)展過程中可能起到重要協(xié)同作用,有望成為子宮內(nèi)膜癌基因治療的新途徑。
[Abstract]:Objective: to detect the expression of SIRT-1(Silent information regulator 1 (SIRT-1(Silent information regulator 1) and SUMO-1(Small ubiquitin-related modifier-1 (SUMO-1(Small ubiquitin-related modifier-1) in different endometrial tissues and to speculate their possible relationship with the development of endometrial carcinoma. Methods: from October 1st 2014 to June 30th 2016, the expression of SIRT-1(Silent information regulator 1 and SUMO-1(Small ubiquitin-related modifier-1 were collected and preserved. 73 cases of abnormal endometrial tissue were surgically resected and pathologically confirmed in the Gynecology Department of Qingdao University affiliated Hospital and Qingdao Women and Children's Hospital. There were 45 cases of endometrial carcinoma (all adenocarcinoma, 28 cases of atypical hyperplasia of endometrium). 30 cases of normal endometrium were selected after hysterectomy because of simple uterine leiomyoma and confirmed by pathology. SIRT-1 protein and SUMO-1 protein were detected by immunohistochemical method and western-blot method respectively in each group of endometrium group. The level of expression in weaving, The relationship between the expression of endometrial carcinoma and the degree of endometrial lesion and the clinicopathological parameters of endometrial carcinoma was analyzed by statistical method. Results the age area of 45 patients with endometrial carcinoma was analyzed. Among them, 32 cases were 50 years old. The positive expression rate of SIRT-1 protein in normal endometrium, atypical hyperplasia of endometrium and endometrial carcinoma was 6.67%, 42.9% and 62.2%, respectively. The positive expression rate of SUMO-1 protein in normal endometrium, atypical hyperplasia of endometrium and endometrial carcinoma was 6.675.1and 55.6%, respectively, and the positive rate of SUMO-1 protein was increasing in normal endometrium, endometrial atypical hyperplasia and endometrial carcinoma, respectively, and the positive expression rate of SUMO-1 protein in normal endometrium, endometrial atypical hyperplasia and endometrial carcinoma was significantly higher than that in normal endometrium. There was significant difference in the positive rate of the two groups (P 0.05). The positive rates of the two groups in normal endometrium, atypical hyperplasia of endometrium and endometrial carcinoma were 42.2% and 42.2%, respectively. The positive expression rate of the two groups in the group with lymph node metastasis was significantly higher than that in the group with negative lymph node metastasis (P 0.05), and the degree of histological differentiation between the two groups and the histological differentiation of endometrial carcinoma was significantly higher than that in the group with negative lymph node metastasis. Lymph node metastasis and clinical stage of FIGO were related to P0.05, but age was not related to the type of endometrial carcinoma. Conclusion the positive expression rates of SUMO-1 and SIRT-1 in endometrial tissue were different with normal endometrium and atypical hyperplasia of endometrium. The development of endometrial carcinoma shows an increasing trend, which is related to the degree of lymph node metastasis, histological differentiation, and clinical stage of endometrial carcinoma. At the same time, they may play an important synergistic role in the development of endometrial carcinoma, which may be a new way of gene therapy for endometrial carcinoma.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 袁俐;袁夢(mèng)嵐;陳旭紅;姜忠敏;李艷霞;馬曉芳;劉曉智;;SUMO-1及ERα在子宮內(nèi)膜癌中的表達(dá)及相關(guān)性研究[J];國(guó)際婦產(chǎn)科學(xué)雜志;2015年04期

2 Wanqing Chen;;Cancer statistics: updated cancer burden in China[J];Chinese Journal of Cancer Research;2015年01期

3 王鑫鑫;彭正;李楊;王華;王立生;陳凜;;SIRT1在胃癌組織、細(xì)胞中的表達(dá)及意義[J];山東醫(yī)藥;2014年12期

4 閔玲;鐘亮星;陳琳娜;鄧粵敏;;血清TSGF、SCC聯(lián)合檢測(cè)在宮頸癌診斷中的應(yīng)用價(jià)值[J];實(shí)用醫(yī)學(xué)雜志;2014年06期

5 樊林;陳銳;趙偉;劉俊松;張正良;李亮;王澤星;車向明;;Sirt1、P53及P-gp在胃癌中的表達(dá)及其臨床意義[J];西安交通大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2013年05期

6 楊文嘉;王冬來;朱衛(wèi)國(guó);;去乙酰化酶SIRT1的表達(dá)及活性調(diào)控機(jī)制[J];遺傳;2010年10期

7 劉世榮;何維;;SUMO化修飾:一種多功能的蛋白質(zhì)翻譯后修飾方式[J];醫(yī)學(xué)分子生物學(xué)雜志;2006年03期

，

本文編號(hào)：1575615